mTOR inhibitor (rapamycin) and EGFR inhibitor (erlotinib) block downstream mTOR signaling, promote nuclear PML expression in GBM that targets and inhibits PI3K-Akt/mTOR signaling, slowing down cell proliferation. The gene discussed is EGFR; the disease is glioblastoma.